

1 September 2015

ANP Licensing Partner Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

Antisense Therapeutics Ltd (ANP) wishes to advise of news from its ATL1103 licensing partner Cortendo AB, that Cortendo has filed a registration statement on Form F-1 with the US Securities and Exchange Commission relating to the proposed initial public offering of its ordinary shares on the NASDAQ Global Market.

Please see attached press release from Cortendo.

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (0)3 9827 8999

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

CORTENDO

Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

August 31, 2015 – Göteborg, Sweden and Trevese, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A], today announced it has filed a registration statement on Form F-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Cortendo AB has applied to list its ordinary shares on The NASDAQ Global Market under the ticker symbol “SBBP.”

BofA Merrill Lynch and Stifel are acting as joint book-running managers of the proposed offering. JMP Securities is acting as lead manager, Roth Capital Partners is acting as co-manager and Arctic Securities is acting as an advisor.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained, when available from: BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attention: Prospectus Department or by emailing dg.prospectus_requests@baml.com; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

A registration statement on Form F-1 relating to the proposed offering has been filed with the Securities and Exchange Commission but has not yet become effective. The shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts:

Cortendo AB

Corporate and Media Relations

Elixir Health Public Relations

Lindsay Rocco

+1 862-596-1304

lrocco@elixirhealthpr.com

CORTENDO

Investor Relations

ICR Inc.

Stephanie Carrington

+1 646-277-1282

Stephanie.Carrington@icrinc.com

Sweden

Box 47

SE-433 21 Partille

Tel. / Fax. +46 (0) 31-263010

USA

900 Northbrook Drive

Suite 200

Treose, PA 19053

Tel. +1 610-254-9200

Fax. +1 215-355-7389